OBEXELIMAB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 14:23:27 GMT 2023` Edited by `admin` on `Sat Dec 16 14:23:27 GMT 2023`
Protein Type	MONOCLONAL ANTIBODY
Protein Sub Type	IGG1
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	RM16A4BA8R
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OBEXELIMAB

Official Name

English

XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)

Common Name

English

OBEXELIMAB [USAN]

Common Name

English

XMAB5871

Code

English

IMMUNOGLOBULIN G1, ANTI-(HUMAN CD19 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB5871 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL XMAB5871 LIGHT CHAIN, DIMER

Systematic Name

English

obexelimab [INN]

Common Name

English

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS B-LYMPHOCYTE ANTIGEN CD19 (DIFFERENTIATION ANTIGEN CD19T-CELL SURFACE ANTIGEN LEU-12))HUMANIZED MOUSE MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-451) (MUS MUSCULUS VH (IGHV1-14*01 (78%) (IGHD)-IGHJ4*01 (100%))

Systematic Name

English

XMAB-5871

Code

English

Classification Tree Code System Code

FDA ORPHAN DRUG

566516

Created by admin on Sat Dec 16 14:23:27 GMT 2023 , Edited by admin on Sat Dec 16 14:23:27 GMT 2023

Code System Code Type Description

USAN

FG-171

Created by admin on Sat Dec 16 14:23:27 GMT 2023 , Edited by admin on Sat Dec 16 14:23:27 GMT 2023

PRIMARY

DRUG BANK

DB15032

Created by admin on Sat Dec 16 14:23:27 GMT 2023 , Edited by admin on Sat Dec 16 14:23:27 GMT 2023

PRIMARY

INN

10898

Created by admin on Sat Dec 16 14:23:27 GMT 2023 , Edited by admin on Sat Dec 16 14:23:27 GMT 2023

PRIMARY

FDA UNII

RM16A4BA8R

Created by admin on Sat Dec 16 14:23:27 GMT 2023 , Edited by admin on Sat Dec 16 14:23:27 GMT 2023

PRIMARY

CAS

1958118-77-8

Created by admin on Sat Dec 16 14:23:27 GMT 2023 , Edited by admin on Sat Dec 16 14:23:27 GMT 2023

NO STRUCTURE GIVEN

CAS

1690307-05-1

Created by admin on Sat Dec 16 14:23:27 GMT 2023 , Edited by admin on Sat Dec 16 14:23:27 GMT 2023

PRIMARY

NCI_THESAURUS

C170236

Created by admin on Sat Dec 16 14:23:27 GMT 2023 , Edited by admin on Sat Dec 16 14:23:27 GMT 2023

PRIMARY

From	To
1_22	1_96
1_148	1_204
1_265	1_325
1_371	1_429
1_224	3_219
1_230	2_230
1_233	2_233
2_22	2_96
2_148	2_204
2_265	2_325
2_371	2_429
2_224	4_219
3_23	3_93
3_139	3_199
4_23	4_93
4_139	4_199

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_301
N	2_301

Related Record Type Details


					IYZ9TI08W3

B-LYMPHOCYTE ANTIGEN CD19

TARGET -> INHIBITOR

Comments:

Co-ligation of CD19 and FcgRIIb leads to downregulation and inhibition of B lineage cells bearing these targets.

Amount:


					BL1QF84VR0

LOW AFFINITY IMMUNOGLOBULIN .GAMMA. FC REGION RECEPTOR II-B

TARGET -> AGONIST

Comments:

Co-ligation of CD19 and FcgRIIb leads to downregulation and inhibition of B lineage cells bearing these targets.

Interaction Type:

BINDING

Amount:

Related Record Type Details


					RM16A4BA8R

ACTIVE MOIETY

Comments:

immunomodulator

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL